Genome-wide association study of prostate cancer-specific survival

Robert Szulkin; Robert Karlsson; Thomas Whitington; Markus Aly; Henrik Gronberg; Rosalind A Eeles; Douglas F Easton; Zsofia Kote-Jarai; Ali Amin Al Olama; Sara Benlloch; Kenneth Muir; Graham G Giles; Melissa C Southey; Liesel M FitzGerald; Brian E Henderson; Fredrick R Schumacher; Christopher A Haiman; Csilla Sipeky; Teuvo L J Tammela; Børge G Nordestgaard; Timothy J Key; Ruth C Travis; David E Neal; Jenny L Donovan; Freddie C Hamdy; Paul D P Pharoah; Nora Pashayan; Kay-Tee Khaw; Janet L Stanford; Stephen N Thibodeau; Shannon K McDonnell; Daniel J Schaid; Christiane Maier; Walther Vogel; Manuel Luedeke; Kathleen Herkommer; Adam S Kibel; Cezary Cybulski; Jan Lubiński; Wojciech Kluźniak; Lisa Cannon-Albright; Hermann Brenner; Volker Herrmann; Bernd Holleczek; Jong Y Park; Thomas A Sellers; Hui-Yi Lim; Chavdar Slavov; Radka P Kaneva; Vanio I Mitev; PRACTICAL consortium

doi:10.1158/1055-9965.epi-15-0543

Genome-wide association study of prostate cancer-specific survival

Robert Szulkin, Robert Karlsson, Thomas Whitington, Markus Aly, Henrik Gronberg, Rosalind A Eeles, Douglas F Easton, Zsofia Kote-Jarai, Ali Amin Al Olama, Sara Benlloch, Kenneth Muir, Graham G Giles, Melissa C Southey, Liesel M FitzGerald, Brian E Henderson, Fredrick R Schumacher, Christopher A Haiman, Csilla Sipeky, Teuvo L J Tammela, Børge G NordestgaardTimothy J Key, Ruth C Travis, David E Neal, Jenny L Donovan, Freddie C Hamdy, Paul D P Pharoah, Nora Pashayan, Kay-Tee Khaw, Janet L Stanford, Stephen N Thibodeau, Shannon K McDonnell, Daniel J Schaid, Christiane Maier, Walther Vogel, Manuel Luedeke, Kathleen Herkommer, Adam S Kibel, Cezary Cybulski, Jan Lubiński, Wojciech Kluźniak, Lisa Cannon-Albright, Hermann Brenner, Volker Herrmann, Bernd Holleczek, Jong Y Park, Thomas A Sellers, Hui-Yi Lim, Chavdar Slavov, Radka P Kaneva, Vanio I Mitev, PRACTICAL consortium

Institut for Klinisk Medicin

24 Citationer (Scopus)

Abstract

BACKGROUND: Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical.

METHODS: We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR).

RESULTS: We observed no significant association between genetic variants and prostate cancer survival.

CONCLUSIONS: Common genetic variants with large impact on prostate cancer survival were not observed in this study.

IMPACT: Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes.

Originalsprog	Engelsk
Tidsskrift	Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Vol/bind	24
Udgave nummer	11
Sider (fra-til)	1796-1800
Antal sider	5
ISSN	1055-9965
DOI	https://doi.org/10.1158/1055-9965.epi-15-0543
Status	Udgivet - nov. 2015

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1158/1055-9965.epi-15-0543

1796.full.pdfForlagets udgivne version, 273 KB

Citationsformater

Szulkin, R., Karlsson, R., Whitington, T., Aly, M., Gronberg, H., Eeles, R. A., Easton, D. F., Kote-Jarai, Z., Al Olama, A. A., Benlloch, S., Muir, K., Giles, G. G., Southey, M. C., FitzGerald, L. M., Henderson, B. E., Schumacher, F. R., Haiman, C. A., Sipeky, C., Tammela, T. L. J., ... PRACTICAL consortium (2015). Genome-wide association study of prostate cancer-specific survival. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 24(11), 1796-1800. https://doi.org/10.1158/1055-9965.epi-15-0543

Genome-wide association study of prostate cancer-specific survival. / Szulkin, Robert; Karlsson, Robert; Whitington, Thomas et al.

I: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Bind 24, Nr. 11, 11.2015, s. 1796-1800.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Szulkin, R, Karlsson, R, Whitington, T, Aly, M, Gronberg, H, Eeles, RA, Easton, DF, Kote-Jarai, Z, Al Olama, AA, Benlloch, S, Muir, K, Giles, GG, Southey, MC, FitzGerald, LM, Henderson, BE, Schumacher, FR, Haiman, CA, Sipeky, C, Tammela, TLJ, Nordestgaard, BG, Key, TJ, Travis, RC, Neal, DE, Donovan, JL, Hamdy, FC, Pharoah, PDP, Pashayan, N, Khaw, K-T, Stanford, JL, Thibodeau, SN, McDonnell, SK, Schaid, DJ, Maier, C, Vogel, W, Luedeke, M, Herkommer, K, Kibel, AS, Cybulski, C, Lubiński, J, Kluźniak, W, Cannon-Albright, L, Brenner, H, Herrmann, V, Holleczek, B, Park, JY, Sellers, TA, Lim, H-Y, Slavov, C, Kaneva, RP, Mitev, VI & PRACTICAL consortium 2015, 'Genome-wide association study of prostate cancer-specific survival', Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, bind 24, nr. 11, s. 1796-1800. https://doi.org/10.1158/1055-9965.epi-15-0543

Szulkin R, Karlsson R, Whitington T, Aly M, Gronberg H, Eeles RA et al. Genome-wide association study of prostate cancer-specific survival. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2015 nov.;24(11):1796-1800. doi: 10.1158/1055-9965.epi-15-0543

@article{b2e8953472574c4a84ed8fd5430d94b1,

title = "Genome-wide association study of prostate cancer-specific survival",

abstract = "BACKGROUND: Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical.METHODS: We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR).RESULTS: We observed no significant association between genetic variants and prostate cancer survival.CONCLUSIONS: Common genetic variants with large impact on prostate cancer survival were not observed in this study.IMPACT: Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes.",

author = "Robert Szulkin and Robert Karlsson and Thomas Whitington and Markus Aly and Henrik Gronberg and Eeles, {Rosalind A} and Easton, {Douglas F} and Zsofia Kote-Jarai and {Al Olama}, {Ali Amin} and Sara Benlloch and Kenneth Muir and Giles, {Graham G} and Southey, {Melissa C} and FitzGerald, {Liesel M} and Henderson, {Brian E} and Schumacher, {Fredrick R} and Haiman, {Christopher A} and Csilla Sipeky and Tammela, {Teuvo L J} and Nordestgaard, {B{\o}rge G} and Key, {Timothy J} and Travis, {Ruth C} and Neal, {David E} and Donovan, {Jenny L} and Hamdy, {Freddie C} and Pharoah, {Paul D P} and Nora Pashayan and Kay-Tee Khaw and Stanford, {Janet L} and Thibodeau, {Stephen N} and McDonnell, {Shannon K} and Schaid, {Daniel J} and Christiane Maier and Walther Vogel and Manuel Luedeke and Kathleen Herkommer and Kibel, {Adam S} and Cezary Cybulski and Jan Lubi{\'n}ski and Wojciech Klu{\'z}niak and Lisa Cannon-Albright and Hermann Brenner and Volker Herrmann and Bernd Holleczek and Park, {Jong Y} and Sellers, {Thomas A} and Hui-Yi Lim and Chavdar Slavov and Kaneva, {Radka P} and Mitev, {Vanio I} and {PRACTICAL consortium}",

note = "{\textcopyright}2015 American Association for Cancer Research.",

year = "2015",

month = nov,

doi = "10.1158/1055-9965.epi-15-0543",

language = "English",

volume = "24",

pages = "1796--1800",

journal = "Cancer Epidemiology, Biomarkers & Prevention",

issn = "1055-9965",

publisher = "American Association for Cancer Research (A A C R)",

number = "11",

}

TY - JOUR

T1 - Genome-wide association study of prostate cancer-specific survival

AU - Szulkin, Robert

AU - Karlsson, Robert

AU - Whitington, Thomas

AU - Aly, Markus

AU - Gronberg, Henrik

AU - Eeles, Rosalind A

AU - Easton, Douglas F

AU - Kote-Jarai, Zsofia

AU - Al Olama, Ali Amin

AU - Benlloch, Sara

AU - Muir, Kenneth

AU - Giles, Graham G

AU - Southey, Melissa C

AU - FitzGerald, Liesel M

AU - Henderson, Brian E

AU - Schumacher, Fredrick R

AU - Haiman, Christopher A

AU - Sipeky, Csilla

AU - Tammela, Teuvo L J

AU - Nordestgaard, Børge G

AU - Key, Timothy J

AU - Travis, Ruth C

AU - Neal, David E

AU - Donovan, Jenny L

AU - Hamdy, Freddie C

AU - Pharoah, Paul D P

AU - Pashayan, Nora

AU - Khaw, Kay-Tee

AU - Stanford, Janet L

AU - Thibodeau, Stephen N

AU - McDonnell, Shannon K

AU - Schaid, Daniel J

AU - Maier, Christiane

AU - Vogel, Walther

AU - Luedeke, Manuel

AU - Herkommer, Kathleen

AU - Kibel, Adam S

AU - Cybulski, Cezary

AU - Lubiński, Jan

AU - Kluźniak, Wojciech

AU - Cannon-Albright, Lisa

AU - Brenner, Hermann

AU - Herrmann, Volker

AU - Holleczek, Bernd

AU - Park, Jong Y

AU - Sellers, Thomas A

AU - Lim, Hui-Yi

AU - Slavov, Chavdar

AU - Kaneva, Radka P

AU - Mitev, Vanio I

AU - PRACTICAL consortium

PY - 2015/11

Y1 - 2015/11

N2 - BACKGROUND: Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical.METHODS: We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR).RESULTS: We observed no significant association between genetic variants and prostate cancer survival.CONCLUSIONS: Common genetic variants with large impact on prostate cancer survival were not observed in this study.IMPACT: Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes.

AB - BACKGROUND: Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical.METHODS: We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR).RESULTS: We observed no significant association between genetic variants and prostate cancer survival.CONCLUSIONS: Common genetic variants with large impact on prostate cancer survival were not observed in this study.IMPACT: Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes.

U2 - 10.1158/1055-9965.epi-15-0543

DO - 10.1158/1055-9965.epi-15-0543

M3 - Journal article

C2 - 26307654

SN - 1055-9965

VL - 24

SP - 1796

EP - 1800

JO - Cancer Epidemiology, Biomarkers & Prevention

JF - Cancer Epidemiology, Biomarkers & Prevention

IS - 11

ER -

Genome-wide association study of prostate cancer-specific survival

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater